To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson’s disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
TRPM2 Antibody
Antibody
Rabbit monoclonal antibody directed against human TRPM2. Developed for use in immunoblotting, immunocytochemistry, and immunoprecipitation applications.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
Anticipated Availability: Q4 2027
SMPD1 Antibody
Antibody
Rabbit monoclonal antibody directed against human SMPD1. Developed for use in immunoblotting, immunocytochemistry, and immunoprecipitation applications.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
Anticipated Availability: Q4 2027
MHC-I H2-Kb Antibody
Antibody
Rabbit monoclonal antibody directed against mouse MHC-I H2-Kb for immunoblotting and immunostaining applications. This antibody only reacts with K-B.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
SLC18B1 Antibody
Antibody
Rabbit monoclonal antibody directed against human SLC18B1. Developed for use in immunoblotting, immunocytochemistry, and immunoprecipitation applications.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
Anticipated Availability: Q4 2027
DYRK1A Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse DYRK1A. Developed for use in immunoblotting, immunocytochemistry, immunohistochemistry, and immunoprecipitation applications.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
Anticipated Availability: Q4 2027
ATP13A2 Antibody (Hu - WB)
Antibody
Rabbit monoclonal antibody directed against human ATP13A2 for immunoblotting applications. The epitope of this antibody was mapped to AA581-586.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
CTSB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CTSB for heterozygous and homozygous knockout. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).
ITPKB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered homozygous knockout of ITPKB.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
Estimated Availability: Late 2026
SPTSSB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered homozygous knockout of SPTSSB.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
Estimated Availability: Late 2026
NOD2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in NOD2, including heterozygous and homozygous knockout.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
Have questions or need additional information?
Email [email protected] with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic